Kenichi Kazuta

698 citations

15 papers · 515 indexed · h-index 11

Endocrinology, Diabetes and Metabolism top 2%
Molecular Biology
Surgery
Pharmacology
Nephrology top 10%

Co-authors: Atsunori Kashiwagi Satoshi Yoshida Atsushi Utsuno Itsuro Nagase Eiji Ueyama Hideyuki Takahashi Hiroshi Ishikawa Takanori Shiga
Topics: Diabetes Treatment and Management (13 papers)Metabolism, Diabetes, and Cancer (11 papers)Diabetes Management and Research (9 papers)
Cited by: Endocrinology, Diabetes and Metabolism Nephrology Pharmacology
Journals: Bioorganic & Medicinal Chemistry British Journal of Clinical Pharmacology Diabetes Obesity and Metabolism
Partner nations: Japan Netherlands United States

In The Last Decade

Kenichi Kazuta

14 papers receiving 512 citations

Peers

Countries citing papers authored by Kenichi Kazuta

Since Specialization

Citations

This map shows the geographic impact of Kenichi Kazuta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenichi Kazuta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenichi Kazuta more than expected).

Fields of papers citing papers by Kenichi Kazuta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenichi Kazuta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenichi Kazuta. The network helps show where Kenichi Kazuta may publish in the future.

Co-authorship network of co-authors of Kenichi Kazuta

This figure shows the co-authorship network connecting the top 25 collaborators of Kenichi Kazuta. A scholar is included among the top collaborators of Kenichi Kazuta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenichi Kazuta. Kenichi Kazuta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus 2020 ·Diabetes Therapy ·Masako Saitō,Atsunori Kaibara,Takeshi Kadokura,Junko Toyoshima,Satoshi Yoshida,Kenichi Kazuta,Eiji Ueyama	0
2	Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus 2019 ·British Journal of Clinical Pharmacology ·Masako Saitō,Atsunori Kaibara,Takeshi Kadokura,Junko Toyoshima,Satoshi Yoshida,Kenichi Kazuta,Eiji Ueyama	6
3	Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials 2018 ·Endocrine Journal ·Atsunori Kashiwagi,(unknown),Ichiro Nakamura,(unknown),Kenichi Kazuta,Eiji Ueyama,Hideyuki Takahashi,(unknown)	15
4	Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials 2016 ·Diabetology International ·Atsunori Kashiwagi,Satoshi Yoshida,(unknown),Ichiro Nakamura,Kenichi Kazuta,Eiji Ueyama,Hideyuki Takahashi,(unknown),(unknown),Toshio Ogihara	13
5	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials 2015 ·Journal of Diabetes Investigation ·Atsunori Kashiwagi,Satoshi Yoshida,Ichiro Nakamura,Kenichi Kazuta,Eiji Ueyama,Hideyuki Takahashi,(unknown),(unknown),(unknown)	26
6	Long-term safety, tolerability and efficacy of ipragliflozin in combination with an α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus inadequately controlled with an α-glucosidase inhibitor alone - Aglow study 2014 ·Atsunori Kashiwagi,(unknown),(unknown),Kenichi Kazuta,Atsushi Utsuno,Satoshi Yoshida	2
7	Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study 2014 ·Diabetology International ·Atsunori Kashiwagi,(unknown),Takanori Shiga,Kenichi Kazuta,Atsushi Utsuno,Satoshi Yoshida,Eiji Ueyama	51
8	Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study 2014 ·Diabetes Research and Clinical Practice ·Takeshi Kadokura,(unknown),Atsunori Kashiwagi,Atsushi Utsuno,Kenichi Kazuta,Satoshi Yoshida,Itsuro Nagase,Ronald Smulders,Shigeru Kageyama	30
9	A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study 2014 ·Diabetes Obesity and Metabolism ·Atsunori Kashiwagi,Hideyuki Takahashi,Hiroshi Ishikawa,Satoshi Yoshida,Kenichi Kazuta,Atsushi Utsuno,Eiji Ueyama	97
10	Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study) 2014 ·Diabetology International ·Atsunori Kashiwagi,Takanori Shiga,(unknown),Kenichi Kazuta,Atsushi Utsuno,Satoshi Yoshida,Eiji Ueyama	44
11	Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study 2014 ·Diabetology International ·Atsunori Kashiwagi,Kenichi Kazuta,(unknown),Satoshi Yoshida,Atsushi Utsuno,Itsuro Nagase	71
12	Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus 2013 ·Journal of Diabetes Investigation ·Atsunori Kashiwagi,Kenichi Kazuta,Satoshi Yoshida,Itsuro Nagase	88
13	Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects 2011 ·Diabetology International ·Takeshi Kadokura,Masako Saitō,Atsushi Utsuno,Kenichi Kazuta,Satoshi Yoshida,(unknown),Itsuro Nagase,Shigeru Kageyama	33
14	Synthesis and structure–activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists 2007 ·Bioorganic & Medicinal Chemistry ·Itsuro Shimada,(unknown),Kenichi Kazuta,Hideki Kubota,(unknown),Yasuharu Kimura,(unknown),(unknown),Fumikazu Wanibuchi,Shuichi Sakamoto,(unknown)	32
15	New thiazole derivatives as potent and selective 5-hydroxytriptamine 3 (5-HT3) receptor agonists for the treatment of constipation 2003 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Hiroyuki Koshio,S. Nagashima,Kenichi Kazuta,Mitsuaki Ohta,Shuichi Sakamoto,Hiroyuki Ito,Shinobu Akuzawa,Tetsuo Kiso,Shin‐ichi Tsukamoto,Toshiyasu Mase	7

About Kenichi Kazuta

Kenichi Kazuta is a scholar working on Endocrinology, Diabetes and Metabolism, Gastroenterology and Molecular Biology, having authored 15 papers that have together received 515 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (13 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (9 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (454 citations), Nephrology (63 citations) and Pharmacology (86 citations). Kenichi Kazuta has collaborated with scholars based in Japan, Netherlands and United States. Frequent co-authors include Atsunori Kashiwagi, Satoshi Yoshida, Atsushi Utsuno, Itsuro Nagase, Eiji Ueyama, Hideyuki Takahashi, Satoshi Yoshida, Hiroshi Ishikawa, Takanori Shiga and Takeshi Kadokura. Their work appears in journals such as Bioorganic & Medicinal Chemistry, British Journal of Clinical Pharmacology and Diabetes Obesity and Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact